The adoption of nanomedicine development pipelines that integrate AI, ML, and automation faces several challenges. First, high quality and reproducible data represents a prominent limitation. In part, this results from disparate reporting practices and data from narrow-purpose experimental studies that may not be transferrable for many additional applications. Mining this data from the literature is common but does not overcome limitations in both the quantity and quality of the data. As such, automated experimentation offers a potential means of accruing data. Larger datasets not only improve predictive accuracy, but also model validation. This contributes to higher confidence in the model outputs. Despite the trending popularity of AI, ML, and automation, attitudes among pharmaceutical scientists are another challenge. To attain successful adoption of these tools, better strategies are needed to harmonize experimental data and assess how it can be used to develop new nanoformulations. Better curated data also supports expanding applications for data-driven approaches. One of these areas is evaluating biological efficacy of nanomedicines and their interactions in vivo. For instance, a pertinent aspect of NP biodistribution, and in turn safety, is the formation of a protein corona, the layer of adsorbed biomolecules on its surface . Recent ML efforts have shown promising results in identifying useful descriptors and understanding which NP features contribute to this phenomenon . The appeal of these approaches is that predictions can be made on heterogenous data (i.e., the multidimensional NP properties and components of the protein corona), which facilitate subsequent detailed characterization . Although comprehensive understanding and interpretation remains a challenge, leveraging ML algorithms by modeling these complex interactions and building on previous efforts will help to support preclinical to clinical translation. A final challenge relates to expertise. There is a need for pharmaceutical scientists to wield a thorough understanding of AI/ML, and/or automating experimental methods, if they choose to deploy these tools. This invites cross-disciplinary collaboration and complementary perspectives to develop validated systems.